Acticor Biotech Announces the Completion of Enrollment in its GARDEN clinical trial, a COVID-19-induced Acute Respiratory Distress Syndrome Efficacy Study

Acticor Biotech, a clinical stage biotechnology company developing an innovative drug for the acute phase of ischemic stroke and thrombotic diseases, today announces the completion of recruitment in GARDEN, its phase 2 clinical study on the use of glenzocimab, a novel humanized monoclonal antibody fragment, in patients with COVID-19- induced Acute Respiratory Distress Syndrome (ARDS). [...]

Initial Public Offering on Euronext Growth® Paris • See details